Balance Sheet
Cash Flow Statement
AcquisitionsCapital ExpendituresCapital ExpendituresCash from Financing ActivitiesCash from Financing ActivitiesCash from Investing ActivitiesCash from Investing ActivitiesCash from OperationsCash from OperationsChange in Account PayablesChange in Account PayablesChange in Accured ExpensesChange in Accured ExpensesChange in CashChange in IntangiblesChange in IntangiblesChange in InventoryChange in InventoryChange in ReceivablesChange in ReceivablesChange in TaxesChange in TaxesDeferred TaxesDepreciation & Amortization (CF)Depreciation & Amortization (CF)Free Cash FlowFree Cash FlowGains from Investment SecuritiesGains from Investment SecuritiesGains from Sales and DivestituresGains from Sales and DivestituresLong-Term Debt RepaymentsNet Cash FlowNet Cash FlowNet IncomeNon-cash ItemsNon-cash ItemsOther Working Capital ChangesOther Working Capital ChangesShare-based CompensationShare-based CompensationShares IssuedShares Repurchased
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Tactile Systems Technology (TCMD) Asset Writedowns and Impairment (2016 - 2020)

Tactile Systems Technology (TCMD) reported Asset Writedowns and Impairment of $4.0 million for Q2 2020, up 1438.46% on a QoQ basis from $260000.0 in Q3 2017.

Tactile Systems Technology (TCMD) has 3 years of Asset Writedowns and Impairment data on file, last reported at $4.0 million in Q2 2020.

  • Quarterly Asset Writedowns and Impairment changed N/A year-over-year to $4.0 million in Q2 2020, while the trailing twelve-month figure through Dec 2020 was $4.4 million (changed N/A YoY) and the FY2020 annual result came in at $4.0 million, changed N/A from the prior year.
  • Asset Writedowns and Impairment advanced to $4.0 million in Q2 2020 per TCMD's latest filing, from $260000.0 in the prior quarter.
  • Across five years, Asset Writedowns and Impairment topped out at $4.0 million in Q2 2020 and bottomed at $165000.0 in Q3 2016.
  • The 3-year median for Asset Writedowns and Impairment is $260000.0 (2017), against an average of $1.5 million.
  • Peak annual rise in Asset Writedowns and Impairment reached 57.58% in 2017, while the deepest fall reached 57.58% in 2017.
  • Tracing TCMD's Asset Writedowns and Impairment over 3 years: stood at $165000.0 in 2016, then surged by 57.58% to $260000.0 in 2017, then soared by 1438.46% to $4.0 million in 2020.
  • Per Business Quant, the three latest TCMD Asset Writedowns and Impairment figures stand at $4.0 million (Q2 2020), $260000.0 (Q3 2017), and $165000.0 (Q3 2016).

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr)
1 Abbott Laboratories 152.82 Bn 146.17 Bn 6.27 Bn
2 Stryker 115.07 Bn 112.19 Bn 3.81 Bn
3 Medtronic 95.25 Bn 87.08 Bn 5.76 Bn
4 Boston Scientific 71.38 Bn 70.17 Bn 3.61 Bn
5 Edwards Lifesciences 51.08 Bn 47.41 Bn 1.29 Bn
6 Koninklijke Philips 29.38 Bn 26.07 Bn 2.07 Bn
7 Dexcom 28.84 Bn 27.72 Bn 750.30 Mn
8 GE HealthCare Technologies 28.56 Bn 26.49 Bn 1.98 Bn
9 Steris 20.71 Bn 20.30 Bn 697.10 Mn
10 Tactile Systems Technology 539.21 Mn 449.02 Mn 57.61 Mn

Historic Data

Download Data 🔒
DateValue
Jun 30, 2020 4.00 Mn
Jun 30, 2020 4.00 Mn
Sep 30, 2017 260,000.00
Sep 30, 2017 260,000.00
Sep 30, 2016 165,000.00
Sep 30, 2016 165,000.00